Home
/ COT Orthopedics and Traumatology Center of Rosario
/ Competitors

COT Orthopedics and Traumatology Center of Rosario Competitors and Similar CompaniesClear all

COT Orthopedics and Traumatology Center of Rosario's competitors and similar companies include Oriol Health Care, Texas Medical Center, Centro Médico Del Sol and Novo Integrated Sciences.

	COT Orthopedics and Traumatology Center of Rosario COT Orthopedics and Traumatology Center of Rosario is a provider of healthcare services.	Oriol Health Care Oriol Health Care is a healthcare company that providing rehab services.	Texas Medical Center Texas Medical Center is a medical complex, practicing patient care, research, education, and prevention.	Centro Médico Del Sol Centro Médico Del Sol is a provider of healthcare services.	Novo Integrated Sciences Novo Integrated Sciences is a provider of healthcare solutions.
Founding Date	Founding Date N/A	Founding Date 1964	Founding Date 1945	Founding Date N/A	Founding Date 2000
Type	Type Private	Type Private	Type Private	Type Private	Type Public
Tags	Tags Healthcare medical diagnostics rehabilitation surgical solutions therapy	Tags Healthcare fitness & wellness medical diagnostics rehabilitation surgical solutions therapy	Tags Healthcare clinical research emergency medical diagnostics rehabilitation surgical solutions therapy	Tags Healthcare dental medical diagnostics rehabilitation surgical solutions therapy	Tags Healthcare medical diagnostics rehabilitation therapy
Locations	Locations Rosario, AR HQ	Locations Holden, US HQ West Boylston, US	Locations Houston, US HQ Houston, US	Locations Rincón de Milberg, AR HQ	Locations Bellevue, US HQ Las Vegas, US
Employees	Employees N/A	Employees 931% decrease	Employees 3691% increase	Employees 622% increase	Employees 115
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $112.7m (FY, 2019)	Revenue (est.) N/A	Revenue (est.) $13.3m (FY, 2024)
Net income	Net income N/A	Net income N/A	Net income $39.3m (FY, 2019)	Net income N/A	Net income ($16.1m) (FY, 2024)